{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Holte H"],"funding":["NCI NIH HHS"],"pagination":["225-234"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6530911"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["183(2)"],"pubmed_abstract":["Patients with mantle cell lymphoma (MCL) generally have a dismal prognosis. Intensified induction treatment with rituximab and high dose cytarabine (R_HDAC), and consolidation with high-dose therapy with autologous stem cell support has resulted in 10-year overall survival (OS) higher than 60%. However, the clinical course varies. Diagnostic tools capable of stratifying patients include the MCL International Prognostic Index (MIPI), gene expression-based proliferation signature, Ki-67 proliferation index or tumour cell morphology. Here, we tested the performance of a newly developed Nanostring-based RNA expression-based proliferation assay (MCL35) on formalin-fixed paraffin-embedded tumour tissue from younger patients recruited in or treated according to Nordic MCL protocols compared to th"],"journal":["British journal of haematology"],"pubmed_title":["The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy."],"pmcid":["PMC6530911"],"funding_grant_id":["UH2 CA217847"],"pubmed_authors":["Beiske K","Myklebust J","Smeland EB","Holte H","Blaker YN","Kvaloy S","Lingjaerde OC","Kolstad A","Boyle M","Rimsza LM","Rosenwald A","Scott DW","Troen G"],"additional_accession":[]},"is_claimable":false,"name":"The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.","description":"Patients with mantle cell lymphoma (MCL) generally have a dismal prognosis. Intensified induction treatment with rituximab and high dose cytarabine (R_HDAC), and consolidation with high-dose therapy with autologous stem cell support has resulted in 10-year overall survival (OS) higher than 60%. However, the clinical course varies. Diagnostic tools capable of stratifying patients include the MCL International Prognostic Index (MIPI), gene expression-based proliferation signature, Ki-67 proliferation index or tumour cell morphology. Here, we tested the performance of a newly developed Nanostring-based RNA expression-based proliferation assay (MCL35) on formalin-fixed paraffin-embedded tumour tissue from younger patients recruited in or treated according to Nordic MCL protocols compared to th","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2025-05-29T20:30:47.902Z","creation":"2025-05-29T20:30:47.902Z"},"accession":"S-EPMC6530911","cross_references":{"pubmed":["30080252"],"doi":["10.1111/bjh.15518"]}}